Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 39Active not recruiting 27Terminated 26Completed 25Unknown 8Withdrawn 2Not yet recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 15Thoracic 13Head & Neck 9Breast 9Genitourinary 8Gynecologic 7CNS 5Dermatologic 4Tumor-Agnostic 2Other solid neoplasm 2Lymphoid 2Plasma cell 1

Conditions

Mesothelioma, Malignant 1Locally Advanced or Metastatic Solid Tumors 1

Interventions

Injections 9Interviews as Topic 4Cisplatin 4Carboplatin 4toripalimab 3fludarabine 3envafolimab 3Pemetrexed 3Iodine-125 3Immune Checkpoint Inhibitors 3Fluorodeoxyglucose F18 3tislelizumab 2pembrolizumab 2Paclitaxel 2Oxaliplatin 2Drug Therapy 2Cyclophosphamide 2Cryosurgery 2Capecitabine 2Blood Specimen Collection 2trastuzumab deruxtecan 1spartalizumab 1somatostatin receptor 2 1regorafenib 1olaparib 1nabiximols 1malic acid 1lenvatinib 1ivarmacitinib 1irinotecan sucrosofate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × pembrolizumab × Other solid neoplasm × Clear all
NCT07469774 2026-03-13

BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Biocity Biopharmaceutics Co., Ltd.

Phase 1/2 Not yet recruiting
111 enrolled
Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

NCT05425576 2024-03-15

OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition

Mateon Therapeutics

Phase 2 Not yet recruiting
63 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡